Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy.

Zhou Q, Zhang J, Zhang J, Liang S, Cai D, Xiao H, Zhu Y, Xiang W, Rodrigues-Lima F, Chi J, Guidez F, Wang L

Biol Direct. 2024 01 4;19(1):6

WHIM Syndrome-linked CXCR4 mutations drive osteoporosis.

Anginot A, Nguyen J, Abou Nader Z, Rondeau V, Bonaud A, Kalogeraki M, Boutin A, Lemos JP, Bisio V, Koenen J, Hanna Doumit Sakr L, Picart A, Coudert A, Provot S, Dulphy N, Aurrand-Lions M, Mancini SJC, Lazennec G, McDermott DH, Guidez F, Blin-Wakkach C, Murphy PM, Cohen-Solal M, Espéli M, Rouleau M, Balabanian K

Nat Commun. 2023 04 12;14(1):2058

Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation.

Boy M, Bisio V, Zhao LP, Guidez F, Schell B, Lereclus E, Henry G, Villemonteix J, Rodrigues-Lima F, Gagne K, Retiere C, Larcher L, Kim R, Clappier E, Sebert M, Mekinian A, Fain O, Caignard A, Espeli M, Balabanian K, Toubert A, Fenaux P, Ades L, Dulphy N

Nat Commun. 2023 02 3;14(1):588

Repeat Element Activation-Driven Inflammation: Role of NFκB and Implications in Normal Development and Cancer?

Dumetier B, Sauter C, Hajmirza A, Pernon B, Aucagne R, Fournier C, Row C, Guidez F, Rossi C, Lepage C, Delva L, Callanan MB

Biomedicines. 2022 12 1;10(12):

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies.

Sauter C, Simonet J, Guidez F, Dumétier B, Pernon B, Callanan M, Bastie JN, Aucagne R, Delva L

Cancers (Basel). 2022 11 5;14(21):

BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.

Gorombei P, Guidez F, Ganesan S, Chiquet M, Pellagatti A, Goursaud L, Tekin N, Beurlet S, Patel S, Guerenne L, Le Pogam C, Setterblad N, de la Grange P, LeBoeuf C, Janin A, Noguera ME, Sarda-Mantel L, Merlet P, Boultwood J, Konopleva M, Andreeff M, West R, Pla M, Adès L, Fenaux P, Krief P, Chomienne C, Omidvar N, Padua RA

Int J Mol Sci. 2021 09 30;22(19):

The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).

Berthelet J, Michail C, Bui LC, Le Coadou L, Sirri V, Wang L, Dulphy N, Dupret JM, Chomienne C, Guidez F, Rodrigues-Lima F

Mol Pharmacol. 2021 09;100(3):283-294

PLZF Acetylation Levels Regulate NKT Cell Differentiation.

Klibi J, Joseph C, Delord M, Teissandier A, Lucas B, Chomienne C, Toubert A, Bourc'his D, Guidez F, Benlagha K

J Immunol. 2021 08 1;207(3):809-823

Human CREBBP acetyltransferase is impaired by etoposide quinone, an oxidative and leukemogenic metabolite of the anticancer drug etoposide through modification of redox-sensitive zinc-finger cysteine residues.

Zhang W, Berthelet J, Michail C, Bui LC, Gou P, Liu R, Duval R, Renault J, Dupret JM, Guidez F, Chomienne C, Rodrigues Lima F

Free Radic Biol Med. 2021 01;162:27-37

Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.

Duval R, Bui LC, Mathieu C, Nian Q, Berthelet J, Xu X, Haddad I, Vinh J, Dupret JM, Busi F, Guidez F, Chomienne C, Rodrigues-Lima F

J Biol Chem. 2019 08 16;294(33):12483-12494

T-Cell Protein Tyrosine Phosphatase Is Irreversibly Inhibited by Etoposide-Quinone, a Reactive Metabolite of the Chemotherapy Drug Etoposide.

Nian Q, Berthelet J, Zhang W, Bui LC, Liu R, Xu X, Duval R, Ganesan S, Leger T, Chomienne C, Busi F, Guidez F, Dupret JM, Rodrigues Lima F

Mol Pharmacol. 2019 08;96(2):297-306

Studies in an Early Development Window Unveils a Severe HSC Defect in both Murine and Human Fanconi Anemia.

Domenech C, Maillard L, Rousseau A, Guidez F, Petit L, Pla M, Clay D, Guimiot F, Sanfilippo S, Jacques S, de la Grange P, Robil N, Soulier J, Souyri M

Stem Cell Reports. 2018 11 13;11(5):1075-1091

GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.

Guerenne L, Beurlet S, Said M, Gorombei P, Le Pogam C, Guidez F, de la Grange P, Omidvar N, Vanneaux V, Mills K, Mufti GJ, Sarda-Mantel L, Noguera ME, Pla M, Fenaux P, Padua RA, Chomienne C, Krief P

J Hematol Oncol. 2016 01 27;9:5

Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.

Zassadowski F, Pokorna K, Ferre N, Guidez F, Llopis L, Chourbagi O, Chopin M, Poupon J, Fenaux P, Ann Padua R, Pla M, Chomienne C, Cassinat B

Leukemia. 2015 12;29(12):2277-84

Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.

Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O, Lainey E, Nouri K, Nakhaei-Rad S, Dvorsky R, Lachenaud J, Pereira S, Vivent J, Verger E, Vidaud D, Galambrun C, Picard C, Petit A, Contet A, Poirée M, Sirvent N, Méchinaud F, Adjaoud D, Paillard C, Nelken B, Reguerre Y, Bertrand Y, Häussinger D, Dalle JH, Ahmadian MR, Baruchel A, Chomienne C, Cavé H

Nat Genet. 2015 11;47(11):1334-40

An acetyltransferase assay for CREB-binding protein based on reverse phase-ultra-fast liquid chromatography of fluorescent histone H3 peptides.

Duval R, Fritsch L, Bui LC, Berthelet J, Guidez F, Mathieu C, Dupret JM, Chomienne C, Ait-Si-Ali S, Rodrigues-Lima F

Anal Biochem. 2015 10 1;486:35-7

Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases.

McConnell MJ, Durand L, Langley E, Coste-Sarguet L, Zelent A, Chomienne C, Kouzarides T, Licht JD, Guidez F

Epigenetics Chromatin. 2015 09 24;8:38

A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2).

Duval R, Bui LC, Berthelet J, Dairou J, Mathieu C, Guidez F, Dupret JM, Cools J, Chomienne C, Rodrigues-Lima F

Sci Rep. 2015 06 4;5:10750

HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.

Mielcarek M, Zielonka D, Carnemolla A, Marcinkowski JT, Guidez F

Front Cell Neurosci. 2015 02 24;9:42

[Retrotransposons: selfish DNA or active epigenetic players in somatic cells?].

Guidez F

Med Sci (Paris). 2014 07 11;30(6-7):659-64

The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells.

Puszyk W, Down T, Grimwade D, Chomienne C, Oakey RJ, Solomon E, Guidez F

EMBO J. 2013 07 3;32(13):1941-52

Acute promyelocytic leukemia: a paradigm for differentiation therapy.

Grimwade D, Mistry AR, Solomon E, Guidez F

Cancer Treat Res. 2010 ;145:219-35

Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters.

Petrie K, Guidez F, Zhu J, Howell L, Owen G, Chew YP, Parks S, Waxman S, Licht J, Mittnacht S, Zelent A

Oncogene. 2008 09 4;27(39):5260-6

RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia.

Guidez F, Parks S, Wong H, Jovanovic JV, Mays A, Gilkes AF, Mills KI, Guillemin MC, Hobbs RM, Pandolfi PP, de Thé H, Solomon E, Grimwade D

Proc Natl Acad Sci U S A. 2007 11 20;104(47):18694-9

Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor.

Zheng Y, Balasubramanyam K, Cebrat M, Buck D, Guidez F, Zelent A, Alani RM, Cole PA

J Am Chem Soc. 2005 12 14;127(49):17182-3

Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor.

Altucci L, Rossin A, Hirsch O, Nebbioso A, Vitoux D, Wilhelm E, Guidez F, De Simone M, Schiavone EM, Grimwade D, Zelent A, de Thé H, Gronemeyer H

Cancer Res.. 2005 Oct;65(19):8754-65

Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated

Xu K, Guidez F, Glasow A, Chung D, Petrie K, Stegmaier K, Wang KK, Zhang J, Jing Y, Zelent A, Waxman S

Cancer Res. 2005 09 1;65(17):7856-65

Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein.

Guidez F, Howell L, Isalan M, Cebrat M, Alani RM, Ivins S, Hormaeche I, McConnell MJ, Pierce S, Cole PA, Licht J, Zelent A

Mol Cell Biol. 2005 07;25(13):5552-66

1 alpha,25-dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells.

Bastie JN, Balitrand N, Guidez F, Guillemot I, Larghero J, Calabresse C, Chomienne C, Delva L

Mol Endocrinol. 2004 11;18(11):2685-99

Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.

Sun Y, Kim SH, Zhou DC, Ding W, Paietta E, Guidez F, Zelent A, Ramesh KH, Cannizzaro L, Warrell RP, Gallagher RE

Leukemia. 2004 07;18(7):1258-69

Regulation of Hoxb2 by APL-associated PLZF protein.

Ivins S, Pemberton K, Guidez F, Howell L, Krumlauf R, Zelent A

Oncogene. 2003 06 12;22(24):3685-97

The histone deacetylase 9 gene encodes multiple protein isoforms.

Petrie K, Guidez F, Howell L, Healy L, Waxman S, Greaves M, Zelent A

J Biol Chem. 2003 05 2;278(18):16059-72

Translocations of the RARalpha gene in acute promyelocytic leukemia.

Zelent A, Guidez F, Melnick A, Waxman S, Licht JD

Oncogene. 2001 10 29;20(49):7186-203

Role of nuclear receptor corepressors in leukemogenesis.

Guidez F, Zelent A

Curr Top Microbiol Immunol. 2001 ;254:165-85

Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF.

Dhordain P, Albagli O, Honore N, Guidez F, Lantoine D, Schmid M, The HD, Zelent A, Koken MH

Oncogene. 2000 12 14;19(54):6240-50

Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein.

Guidez F, Petrie K, Ford AM, Lu H, Bennett CA, MacGregor A, Hannemann J, Ito Y, Ghysdael J, Greaves M, Wiedemann LM, Zelent A

Blood. 2000 10 1;96(7):2557-61

Differential utilization of Ras signaling pathways by macrophage colony-stimulating factor (CSF) and granulocyte-macrophage CSF receptors during macrophage differentiation.

Guidez F, Li AC, Horvai A, Welch JS, Glass CK

Mol Cell Biol. 1998 07;18(7):3851-61

Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.

Guidez F, Ivins S, Zhu J, Söderström M, Waxman S, Zelent A

Blood. 1998 04 15;91(8):2634-42

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP

Nat Genet. 1998 02;18(2):126-35

Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein.

Dong S, Zhu J, Reid A, Strutt P, Guidez F, Zhong HJ, Wang ZY, Licht J, Waxman S, Chomienne C, Chen Z, Zelent A, Chen SJ

Proc Natl Acad Sci U S A. 1996 04 16;93(8):3624-9

[Nuclear receptors and ontogenesis of the hematopoietic tissue].

Chomienne C, Guidez F, Micléa JM, Bastie JN, Delva L, Rousselot P, Ballerini P

C R Seances Soc Biol Fil. 1995 ;189(4):493-501

Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells.

Dubois C, Schlageter MH, de Gentile A, Guidez F, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y

Blood. 1994 06 1;83(11):3264-70

PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors.

Chen Z, Guidez F, Rousselot P, Agadir A, Chen SJ, Wang ZY, Degos L, Zelent A, Waxman S, Chomienne C

Proc Natl Acad Sci U S A. 1994 02 1;91(3):1178-82

Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient.

Guidez F, Huang W, Tong JH, Dubois C, Balitrand N, Waxman S, Michaux JL, Martiat P, Degos L, Chen Z

Leukemia. 1994 02;8(2):312-7

The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells.

Rousselot P, Hardas B, Patel A, Guidez F, Gäken J, Castaigne S, Dejean A, de Thé H, Degos L, Farzaneh F

Oncogene. 1994 02;9(2):545-51

Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients.

Cornic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C

Cancer Res. 1992 06 15;52(12):3329-34

[Mechanism of action of retinoids in a new therapeutic approach to acute promyelocytic leukemia].

Cornic M, Guidez F, Delva L, Agadir A, Degos L, Chomienne C

Bull Cancer. 1992 ;79(7):697-704

Retinoic acid inhibits the expression of cytidine deaminase linked to the differentiation of the human leukemic cell line HL-60.

Guidez F, Pérignon JL, Houllier AM, Balitrand N, Abita JP

Leukemia. 1991 08;5(8):699-703

Dr GUIDEZ Fabien

Fiche personne

coordonnées

Territoire

Statut

affiliation

équipes/plateformes

Publications